Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Val Gebski

Showing results (1-10 of 248) with videos related to

Pageof 25
Sort By:
The Lancet. Oncology|December 17, 2004
Clinical trial design in oncology: assessment of outcomesVal Gebski
JAMA|September 8, 2018
Lowering the P Value ThresholdVal Gebski, Karen Byth
Clinical Trials (London, England)|November 11, 2005
Factorial designs: a graphical aid for choosing study designs accounting for interactionKaren Byth, Val Gebski
Internal Medicine Journal|November 3, 2018
Re: Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dyingMarion Harris, Val Gebski
The Medical Journal of Australia|October 17, 2002
Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects?Anthony C Keech, Val Gebski
Lancet (London, England)|May 11, 2010
Procalcitonin in intensive care units: the PRORATA trialWilliam Tarnow-Mordi, Val Gebski
BMC Medical Research Methodology|April 6, 2017
The importance of censoring in competing risks analysis of the subdistribution hazardMark W Donoghoe, Val Gebski
JAMA Oncology|December 7, 2018
Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor 2-Positive Breast Cancer-ReplyVal Gebski, Teppo Huttunen, Heikki Joensuu
BMJ Quality & Safety|August 21, 2013
Identification of doctors at risk of recurrent complaints: a national study of healthcare complaints in AustraliaAndreas Obermair, Monika Janda, Val Gebski
American Journal of Obstetrics and Gynecology|March 14, 2018
All-cause death in young women with endometrial cancer who receive progesterone therapyAndreas Obermair, Monika Janda, Val Gebski
Pageof 25

Showing results (1-10 of 248) with videos related to

Sort By:
Pageof 25
The Lancet. Oncology|December 17, 2004
Clinical trial design in oncology: assessment of outcomesVal Gebski
JAMA|September 8, 2018
Lowering the P Value ThresholdVal Gebski, Karen Byth
Clinical Trials (London, England)|November 11, 2005
Factorial designs: a graphical aid for choosing study designs accounting for interactionKaren Byth, Val Gebski
Internal Medicine Journal|November 3, 2018
Re: Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dyingMarion Harris, Val Gebski
The Medical Journal of Australia|October 17, 2002
Managing the resource demands of a large sample size in clinical trials: can you succeed with fewer subjects?Anthony C Keech, Val Gebski
Lancet (London, England)|May 11, 2010
Procalcitonin in intensive care units: the PRORATA trialWilliam Tarnow-Mordi, Val Gebski
BMC Medical Research Methodology|April 6, 2017
The importance of censoring in competing risks analysis of the subdistribution hazardMark W Donoghoe, Val Gebski
JAMA Oncology|December 7, 2018
Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor 2-Positive Breast Cancer-ReplyVal Gebski, Teppo Huttunen, Heikki Joensuu
BMJ Quality & Safety|August 21, 2013
Identification of doctors at risk of recurrent complaints: a national study of healthcare complaints in AustraliaAndreas Obermair, Monika Janda, Val Gebski
American Journal of Obstetrics and Gynecology|March 14, 2018
All-cause death in young women with endometrial cancer who receive progesterone therapyAndreas Obermair, Monika Janda, Val Gebski
Pageof 25